Trial Profile
SHORT-HER: MULTICENTRIC RANDOMISED PHASE III TRIAL OF 2 DIFFERENT ADJUVANT CHEMOTHERAPY REGIMENS PLUS 3 VS 12 MONTHS OF TRASTUZUMAB IN HER2 POSITIVE BREAST CANCER PATIENTS
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 26 Sep 2023
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary) ; Cyclophosphamide; Docetaxel; Doxorubicin; Epirubicin; Fluorouracil; Paclitaxel; Tamoxifen
- Indications Early breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- Acronyms SHORT-HER
- 07 Sep 2023 Results from ShortHER trial, CherLOB , evaluating how molecular heterogeneity affects the pattern of distant relapse in HER2-positive BC, published in the Journal of the National Cancer Institute
- 06 Jun 2023 Results assessing 10-year update of the overall survival, updated DFS and outcomes according to nodal status presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 07 Jun 2022 Results of this post-hoc analysis presented at the 58th Annual Meeting of the American Society of Clinical Oncology